Breaking News3 years ago
GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint
[ad_1] By Michael Susin GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary...
